Navigation Links
PARI Pharma Presents Study Results of Sinus Delivery and Inhaled,Liposomal Ciclosporin A at European Cystic Fibrosis Conference

MUNICH, Germany, June 14, 2007 /PRNewswire/ -- PARI Pharma will present in-vivo study results for their PARI SINUS pulsating drug delivery system as well as lung deposition and pharmacokinetic data of their proprietary inhaled liposomal Ciclosporin A formulation in lung transplant patients at the European Cystic Fibrosis Conference (ECFC) in Belek, Turkey this week.

Continuing their tradition of developing highly advanced inhalation delivery platforms, PARI has created a pulsating sinus drug delivery system to target the upper respiratory tract. Study results at ECFC will focus on visual deposition results using dynamic 81mKr-gas ventilation imaging.

In a separate poster presentation, study results will be presented showing lung deposition and pharmacokinetics of inhaled Ciclosporin A given to 12 lung transplanted patients using PARI Pharma's proprietary liposomal platform technology delivered via a customized eFlow electronic nebulizer. Inhaled Ciclosporin A is a potential therapy for lung transplant patients that is hoped to improve survival rates while reducing side effects by targeting drug delivery of a Ciclosporin A formulation with eFlow so that lower doses of drug may be effective. Using a vibrating membrane, eFlow can produce aerosols with a very high density of active drug, a precisely defined droplet size, and a high proportion of respirable droplets delivered in the shortest possible period of time.

About ECFC

The European Cystic Fibrosis Conference, held by the European Cystic Fibrosis Society, focuses on international advancements in the treatment of cystic fibrosis. Cystic fibrosis is an inherited chronic disease that affects the lungs and digestive systems of an estimated 70,000 children and adults worldwide. Additional information is available online at http://www.europeancfconference.org.

Abo
'"/>




Page: 1 2

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:10/10/2008)...0 /- Inverness Medical,Inno... near-patient,diagnostics, monitoring and health m...n, the Secretary-General of the United Nations, as... of the world,s leading,research-based and generic...s, together with senior officials from the United ...
(Date:10/9/2008)...reased Sales and Marketing Efforts to Accelerate ...tem, MENLO PARK, Calif., Oct. 9 /- E...ces for the percutaneous repair of cardiac valves,...am with the appointment of,Sean Cleary as senior v...,Chris Richardson, as vice president of sales., "...
(Date:10/8/2008)... Animal Use in Cosmetics and Chemicals Testing, A... today announced,that results of a recently comple...lidation study on MatTek,s EpiDerm in vitro human ...ted the required sensitivity and,specificity for E...o animal,testing for determining human skin irrita...
(Date:10/8/2008)...o evaluate TAXUS(R) Element(TM) Platinum Chromium ...ss., Oct. 8 /- Boston Scien...at it has completed enrollment in,the PERSEUS tria...tion,TAXUS(R) Element(TM) paclitaxel-eluting coron...ed nearly 1,500 patients at 100 U.S. and,internati...
Breaking Medicine Technology:Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General 2Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General 3Evalve Expands Executive Leadership Team 2Evalve Expands Executive Leadership Team 3MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4Best Practice Database Supports Bio Pharma M 26A Integration with New Publication 21393 1Best Practice Database Supports Bio Pharma M 26A Integration with New Publication 21393 2Golf cart injuries on the rise 21391 1Golf cart injuries on the rise 21391 2Video 3A The Nevada Division of Insurance Launches 2008 Health Sham Insurance Campaign 21390 1Video 3A The Nevada Division of Insurance Launches 2008 Health Sham Insurance Campaign 21390 2Video 3A The Nevada Division of Insurance Launches 2008 Health Sham Insurance Campaign 21390 3N Y Mets Omar Minaya Recognized at National Brain Cancer Organizations 3rd Annual Gala 21385 1N Y Mets Omar Minaya Recognized at National Brain Cancer Organizations 3rd Annual Gala 21385 2
...ion Pharmaceuticals Inc.,(TSX: TLN) announced toda...al trial investigating ECO-4601 in advanced cancer...f the American,Society of Clinical Oncology (ASCO)... I dose escalation portion of the study, 14,patien...one,glioma), that had completed and not responded ...
...- Imprime PGG(TM), an,investigational new drug fro...response, increases the effectiveness of Avastin(R... new preclinical,research presented yesterday at t...al Meeting in Chicago., Researchers at the Brown C...studied the synergistic effects of Imprime,PGG in ...
Other Medicine Technology:Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 2Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 3Biothera's Imprime PGG Enhanced Effectiveness of Avastin in Cancer,Study 2
(Date:10/10/2008)...Michigan received $5 million from the National Ins...esource of high-quality experimental data sets of ...mputer-aided drug design to a new level. , The ...puter programs that can predict the effectiveness ...ciate professor in the U-M College of Pharmacy and...
(Date:10/10/2008)... Johns Hopkins University School,of Medicine is la...ptimizing Adjuvant Breast Cancer Strategies: From ...ent key research data on the latest advances in,br...ents in the treatment of breast cancer have,led to...ons that are,increasingly tailored to the specific...
(Date:10/10/2008)... The Mobile Massage Team, (http://www.mobilemassag...massage,services for corporate wellness programs, ... today that it is expanding its service area throu...lphia metropolitan region., "We are quite excited...ed, massage programs and services throughout both...
(Date:10/10/2008)...nationally recognized faculty will,present the ver...east,cancer in the multimedia course "Optimizing A...to Treatment Selection" during National Breast,Can...icing oncologists and other interested,health care...t care,advances. This accredited course offers con...
Breaking Medicine News(10 mins):Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
...e of the African naked mole-rat is helping scienti...in humans. Mole-rats are blind, hairless, and li...led over by a queen. In a new study, scientists, ...atures, are hoping to learn more about how stress ...
...ened to nationalise private hospitals if their own... a nationally televised speech, saying that the pr...part of the public health service if they failed t...e also described costs at private clinics as a sym...
... the knot-like structure of enzymes, but theyve be... an understanding of function what the enzyme act...drug discovery, since many of the most successful .... Now, in an expedited article in NATURE, research...
...ped by methane gas is commonplace in developing co... West too. Fiver persons fell victims to the deadl...arm in Shenandoah Valley, Virginia, US Monday even...34, a Mennonite farmer who climbed into the pit to...
Other Medicine News:Health News:Strange Sex Life of Mole-rats may Provide Clues About Human Infertility 2Health News:Translating Structure into Function 2Health News:Five Killed by Methane Gas on Virginia Farm 2Health News:Five Killed by Methane Gas on Virginia Farm 3
The Affinity pacemaker family offers some of today's smallest, truly automatic devices. Featuring the most effective combination of advanced technologies ever seen, the Affinity DR pacemaker incorpor
Innovative new tools for more efficient patient management begin when the pacemaker is implanted. These sophisticated tools are in effect each day, and they help automate follow-up tasks.
The first-ever completely automatic pacemaker, EnPulse offers exclusive features that make it sophisticated yet simple to use. It performs a wide range of diagnostic tests on a regular basis, without
...ystem 3000Dx (GCS3000Dx) is the first microarray i...oratories. The system consists of the FS450Dx Flui...g and staining of the array, the GCS3000Dx Scanner...croarrays to be scanned without operator intervent...
Medicine Products: